Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1048
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStephens, Andrew-
dc.contributor.otherRyland, Georgina-
dc.contributor.otherHunter, Sally-
dc.contributor.otherDoyle, Maria-
dc.contributor.otherCaramia, Franco-
dc.contributor.otherLi, Jason-
dc.contributor.otherRowley, Simone-
dc.contributor.otherChristie, Michael-
dc.contributor.otherAllan, Prue-
dc.contributor.otherBowtell, David-
dc.contributor.otherCampbell, Ian-
dc.contributor.otherGorringe, Kylie-
dc.contributor.otherAustralian Ovarian Cancer Study Group-
dc.date2017-01-
dc.date.accessioned2017-04-28T02:11:24Z-
dc.date.available2017-04-28T02:11:24Z-
dc.date.issued2017-01-
dc.identifier.citationGenome Med. 2017 Jan 12;9(1):1.en_US
dc.identifier.issn1756-994Xen_US
dc.identifier.urihttp://hdl.handle.net/11434/1048-
dc.descriptionERRATUM: There is an error in Additional file 2 for this article [1]. When opening Additional file 2, this links to the incorrect file. NOTES: The online version of the original article can be found at http://dx.doi.org/10.1186/s13073-015-0210-y. ADDITIONAL FILES: Additional file 2: Figure S1. Nucleotide substitution frequency and context. Figure S2. RRAS2 somatic mutation. Figure S3. Genetic comparison between mucinous ovarian tumors and mucinous cancers from other anatomical sites. Figure S4. ELF3 somatic mutations. Figure S5. H&E stained sections of frozen tissues used for exome discovery cohort.en_US
dc.description.abstractERRATUM TO: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. BACKGROUND: Mucinous ovarian tumors are an unusual group of rare neoplasms with an apparently clear progression from benign to borderline to carcinoma, yet with a controversial cell of origin in the ovarian surface epithelium. They are thought to be molecularly distinct from other ovarian tumors but there have been no exome-level sequencing studies performed to date. METHODS: To understand the genetic etiology of mucinous ovarian tumors and assess the presence of novel therapeutic targets or pathways, we undertook exome sequencing of 24 tumors encompassing benign (5), borderline (8) and carcinoma (11) histologies and also assessed a validation cohort of 58 tumors for specific gene regions including exons 4-9 of TP53. RESULTS: The predominant mutational signature was of C>T transitions in a NpCpG context, indicative of deamination of methyl-cytosines. As well as mutations in known drivers (KRAS, BRAF and CDKN2A), we identified a high percentage of carcinomas with TP53 mutations (52 %), and recurrent mutations in RNF43, ELF3, GNAS, ERBB3 and KLF5. CONCLUSIONS: The diversity of mutational targets suggests multiple routes to tumorigenesis in this heterogeneous group of tumors that is generally distinct from other ovarian subtypes.en_US
dc.publisherSpringeren_US
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228100/pdf/13073_2016_Article_392.pdf-
dc.subjectMucinous Ovarian Tumorsen_US
dc.subjectOvarian Surface Epitheliumen_US
dc.subjectGeneticen_US
dc.subjectTherapeutic Targetsen_US
dc.subjectNeoplastic Precursorsen_US
dc.subjectCarcinomasen_US
dc.subjectTumorigenesisen_US
dc.subjectRare Neoplasmsen_US
dc.subjectOvarian Subtypesen_US
dc.subjectEpithelial Ovarian Tumorsen_US
dc.subjectSequencing Studiesen_US
dc.subjectMolecularly Distincten_US
dc.subjectBenignen_US
dc.subjectBorderlineen_US
dc.subjectMOTsen_US
dc.subjectExome Levelen_US
dc.subjectEpworth Research Institute, Epworth HealthCare, Richmond, Victoria Australia.en_US
dc.subjectObstetrics and Gynaecology Clinical Institute, Epworth HealthCare, Victoria, Australia-
dc.titleErratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1186/s13073-016-0392-yen_US
dc.identifier.journaltitleGenome Medicineen_US
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/28081715en_US
dc.description.affiliatesCancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.en_US
dc.description.affiliatesBioinformatics Core Facility, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.en_US
dc.description.affiliatesDepartment of Anatomical Pathology, Royal Melbourne Hospital, Parkville, VIC, Australiaen_US
dc.description.affiliatesDepartment of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.en_US
dc.description.affiliatesCentre for Cancer Research, MIMR-PHI Institute of Medical Research, Clayton, VIC, Australia.en_US
dc.description.affiliatesDepartment of Molecular and Translational Sciences, Monash University, Clayton, VIC, Australia.en_US
dc.description.affiliatesCancer Genetics and Genomics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.en_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.en_US
dc.description.affiliatesDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, Australia.en_US
dc.description.affiliatesDepartment of Pathology, University of Melbourne, Parkville, VIC, Australia.en_US
dc.type.studyortrialCohort Studyen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
Women's and Children's

Files in This Item:
File Description SizeFormat  
Ryland et al.pdf231.94 kBAdobe PDFView/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.